A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study).

Trial Profile

A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Olaparib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms COMETA-Breast
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 3 patients enrolled by 31 January 2018, and 14 active sites out of 16 participants. Primary endpoint analysis is planned for Q2 2020 as per trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top